Showing 2781-2790 of 20410 results for "".
Who Needs a TKI? Identifying the Right Candidates
https://reachmd.com/programs/cme/Who-Needs-a-TKI-Identifying-the-Right-Candidates/54101/Explore the clinical promise of TKIs in managing exudative retinal diseases with insights on mechanisms, delivery, trials, and patient selection.Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
https://reachmd.com/programs/cme/genetic-susceptibility-in-ibd-from-risk-genes-to-clinical-impact/56893/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.Unblocking Clinical Inertia: The CMI Era in oHCM Care
https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/Stay up to date on oHCM care! Tune in to a replay of our EBAC-accredited satellite symposium from ESC Heart Failure 2026 in Barcelona, Spain.Clinical and Safety Outcomes from the LIGHTSITE III Trial
https://reachmd.com/programs/cme/Clinical-and-Safety-Outcomes-from-the-LIGHTSITE-III-Trial/35946/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effPhotobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
https://reachmd.com/programs/cme/Photobiomodulation-A-Non-Invasive-Treatment-for-Ocular-Disease-and-Trauma/35945/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effPartnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
https://reachmd.com/programs/cme/partnering-through-treatment-preparing-for-immunotherapy-in-the-perioperative-setting/57090/Explore perioperative immunotherapy in locally advanced HNSCC through patient–clinician dialogue, clinical evidence, and multidisciplinary care.The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
https://reachmd.com/programs/cme/the-safety-equation-managing-adverse-events-associated-with-csf1r-inhibitors-in-tgct/48910/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
https://reachmd.com/clinical-practice/cardiology/global-burden-of-stroke-and-myocardial-infarction-in-patients-at-high-risk-of-first-mace-insights-from-the-vesalius-real-study/39990/Examine global rates of stroke and MI in patients at high-risk of first MACE without prior events, as explored in the VESALIUS-REAL burden of disease study.Crohn’s & Colitis Congress: A Preview of the “Trends in IBD Care”
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/crohns-colitis-congress-a-preview-of-the-trends-in-ibd-care/10743/Amid recent advances, how can we keep IBD patients at the center of care? That’s what a session at the Crohn’s & Colitis Congress sought to answer.When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
https://reachmd.com/programs/cme/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.